In 1959
January, Shandong Province Changwei Center Pharmaceutical Material Company Pharmaceutical Factory was established.
1964
January, the name of the factory was changed to "Weifang Wholesale Station Processing Factory of China Pharmaceutical Materials Company".
1978
</strong> approved by the Department of Health of Shandong Province (78) LU Wei Drugs No. 83, the heart may be comfortable tablets officially put into production. 1980
January, the name of the factory was changed to "Weifang Traditional Chinese Medicine Factory of Shandong Province"
March, the trademark of "Shoushan" was officially launched. 1990
March, through the health department of shandong province organization of the factory production license acceptance.
1991
January, the name of the factory was restored from "Shandong Weifang Traditional Chinese Medicine Factory" to "Shandong Weifang Traditional Chinese Medicine Factory", the affiliation remained unchanged.
November, Amber Stone Eliminating Punch was awarded the Silver Prize in the 40th Eureka World Invention Expo.
1992
October, the factory was renamed as "Weifang Pharmaceutical Group Corporation Traditional Chinese Medicine Factory", under the leadership of Shandong Weifang Pharmaceutical Group Corporation.
1993
May, Cardiovascular Tablets entered the basic catalog of clinical medicines used in national hospitals.
November, the name of the factory was changed to: "Shandong Weifang Pharmaceutical Group Corporation Traditional Chinese Medicine Factory", under the Shandong Weifang Pharmaceutical Group.
1994
February, the heart can be comfortable tablets, amber elimination of stone punch, children's antipyretic punch was listed in the national Chinese medicine second-class protected varieties, the protection period of seven years.
In March, Xin Ke Shu Tablet was listed in Shanghai public medical catalog.
July, it passed the inspection and acceptance of health license and drug production license organized by Shandong Provincial Health Department.
1996
February, Cardiovascular Tablets were recommended by the State Administration of Traditional Chinese Medicine as a "Famous Brand Product of Chinese Traditional Medicine". In 1997
March, the development of Xinkosu film-coated tablets won the "Second Prize of Scientific and Technological Progress of Shandong Provincial Pharmaceutical Administration".
In May, Xinkosu Tablets were included in the list of Beijing's publicly-funded medical treatment.
At the end of August, the project of expanding the production capacity of the workshop of CardioSol was completed and passed the acceptance.
November, Xinkosu film-coated tablets were listed in the national key new product catalog and received the national key new product certificate.
1998
</strong> In April, Xinkosu film-coated tablets were honored with the Certificate of National Key New Products issued by six ministries and commissions, including the State Science and Technology Commission, the State Taxation Bureau, the State Ministry of Foreign Trade and Economic Cooperation, the State Bureau of Technical Supervision and the State Environmental Protection Bureau.
October, approved by Weifang Municipal People's Government Office Weizhengban Fuzi [1998] No. 120, was designated as a medium (one) type enterprise. In 2000
February, the in vitro diagnostic reagent workshop passed the GMP certification organized by the State Drug Administration.
In May, the company's exclusive traditional Chinese medicine protected variety, Cardiac Kesu Tablets, was listed in the "National Basic Medical Insurance and Work Injury Insurance Drug Catalog".
July, the State Drug Administration announced the first batch of non-prescription drug catalog, with 34 varieties and 36 specifications of products selected.
2001
</strong> In January, the declared Cardiac Kesu Capsules were awarded the second category of protected varieties of national traditional Chinese medicines, with a protection period of 7 years.
February, the declaration of 34 varieties, 35 specifications of non-prescription drugs through the provincial Drug Administration audit and get the certificate.
In the same month, Heart Kesu Tablets, Succinum Antipyretic Granules, and Pediatric Antipyretic Granules were granted the second phase of national TCM protection for a period of 7 years.
In the same month, the "Helicobacter pylori urease diagnostic kit project" was listed as a National Torch Program project by the Ministry of Science and Technology of the People's Republic of China.
In April, the solid preparation workshop successfully passed the GMP certification on-site acceptance organized by the State Drug Administration.
In the same month, Tangerine Pear Paste was granted the second level of protection of the national Chinese medicine protection varieties, with a protection period of 7 years.
2002
</strong> February, Shandong Weifang Pharmaceutical Group Co., Ltd. and Beijing Wohua Bio-technology Co., Ltd. property rights transfer contract signing ceremony was held in Weifang Fuhua Hotel. Zhang Xinqi, Deputy Secretary of Weifang Municipal Party Committee and Executive Vice Mayor of Weifang, attended the signing ceremony and delivered a speech. Zhao Bingxian, Zhao Jun and Zhang Fazhong signed the contract on behalf of Beijing Wohua Biologicals, Weifang Pharmaceutical Group and the company's executives respectively.
February, the first meeting of the first board of directors of Weifang Wohua Pharmaceuticals was held in Weifang, which elected Zhao Bingxian as the chairman of the board of directors, and appointed Zhao Jun as the president of the company, Zhang Fazhong as the executive vice president, Zhang Gao as the chief financial officer, and Huang Gang as the secretary of the board of directors.
February, by the Weifang Municipal Bureau of Industry and Commerce High-tech Industrial Development Zone Branch examination and approval, Weifang Wohua Pharmaceutical Technology Co., Ltd. 2002 was registered and issued a business license, the company's legal representative Zhao Bingxian, Zhao Jun in charge of the company, the registered capital of 16.35 million yuan.
August, Weifang Wohua Pharmaceutical Technology Co., Ltd. Shoushan Xin Ke Shu Research Center was registered.
November, Weifang Economic and Trade Commission, Bureau of Statistics audit approved the company as a medium (two) type enterprises.
In 2003
March, Shandong Wohua Pharmaceutical Technology Co.
In the same month, Antiviral Oral Liquid was listed as a national Chinese medicine grade 2 protected variety with a protection period of 7 years.
April, the company declared "the development of cardiac Kesu drip pill" was listed in the national "863 program", and won the project innovation fund.
In December, the nine dosage forms in the third workshop of the company, which underwent GMP reform, passed the certification at one time. So far, all the dosage forms of the company have passed GMP certification.
In the same month, the production management, warehouse management and financial management formally used Kingdee software, realizing office modernization.
January, 2004
In January, the company implemented the plan of additional issuance, approved by the People's Government of Shandong Province, the company's registered capital increased from 39.99 million yuan to 51.99 million yuan.
April, the company declared the "Cardiac Kesu Drops Renovation Project", "Cardiac Kesu Tablets Renovation Project", "Traditional Chinese Medicine Tablets and Granules Renovation Project", "Bio-diagnostic reagent transformation project" was included in the 2004 technology transformation-oriented plan of Shandong Province, with a total planned investment of 170 million yuan.
In May, the company set up a leading group for stock issuance and listing, a leading group for price, medical insurance, bidding, quality and government relations, and a leading group for internal risk prevention and emergencies.
In the same month, the company was recognized by the Ministry of Science and Technology of the People's Republic of China as a "National Torch Plan Key High-Tech Enterprise".
In June, the project of Xinkexu Drops was listed as "Technology Innovation Project for Small and Medium-sized Enterprises" by the Ministry of Science and Technology of the People's Republic of China, and won the public bidding of "Innovative Drugs and Key Technology Research on Modernization of Traditional Chinese Medicines" organized by the Department of Science and Technology of Shandong Province.
August, by the Shandong Provincial Securities Regulatory Bureau acceptance, the company successfully passed the listing counseling acceptance, and was highly evaluated.
In the same month, the newly added pill dosage form workshop passed the on-site additional acceptance by the provincial drug supervision department.
September, Succinum Antiseptic Granules and Motherwort Oral Liquid were listed in the newly adjusted National Basic Medical Insurance and Workers' Compensation Insurance Drug Catalogue 2005
April, the company passed the listing counseling acceptance organized by Shandong Provincial Securities Supervision Bureau.
In the same month, our Motherwort Oral Liquid was awarded the certificate of national Chinese medicine protection, and was listed as the second grade of national Chinese medicine protection varieties, with a protection period of 7 years.
July, the company commissioned Beijing Zhengbang Advertising Company to design the CIS system formally entered the introduction stage, and formally launched the new logo of Wohua and the advertising slogan of "Good medicine for good people, good medicine for good people". The new logo is composed of blue and green colors, and the whole logo is a distortion of the character "沃", which has a profound meaning;
In September, the in vitro diagnostic reagent workshop of the company passed the GMP re-certification successfully.
November, the company's new plant in the development zone of 150 acres of land index was approved, the new area planning through the development zone planning department for approval.
In 2006
January, the solid preparation workshop successfully passed the on-site acceptance of the second GMP certification organized by the State Drug Administration.
April, the company's "High-tech Industrial Development Zone construction project passed the Shandong Provincial Drug Administration, High-tech Zone, Weifang City Fire Department of the process design demonstration.
May, the company's new plant construction project groundbreaking ceremony was held in the high-tech development zone.
June, "Weifang High-tech Industry Development Special Funds Shandong Wohua Chinese Medicine Research Institute Construction Project" passed the evaluation of Weifang Municipal Government.
In the same month, the enterprise registered the trademark of Wohua and gradually quoted it on the product package.
September, the heart can be comfortable tablets through the China Association of Traditional Chinese Medicine organized by the "quality and price of proprietary Chinese medicines" expert assessment.
On December 18, the 78th meeting of the Audit Committee of the State Securities Supervision and Administration Commission approved the company's application for the issuance of A shares on the Shenzhen Stock Exchange.
2007
January 14, 2007, the company issued 18 million shares on the Shenzhen Stock Exchange at RMB 10.85 per share.
January 24, the company's shares were officially listed on the Shenzhen Stock Exchange SME Board, stock code 002107, the success of the listing and issuance of shares, consolidate and develop the company's core competitive advantages, enhance the company's development momentum, the company has entered a period of rapid development.
January, the company's new drug varieties of cardiac Kesu drip pill through the State Intellectual Property Office of the invention patent approval, becoming the company's first varieties of national patents, patent period of 20 years.
February, the National Development and Reform Commission issued the "National Development and Reform Commission on the establishment of 278 types of proprietary Chinese medicine internal medicine maximum retail price notice", the company's product cardiac kosher tablets (specifications: 0.3g48 film-coated) since March 15 to implement the high quality and excellent price, its maximum retail price adjusted from 19.8 yuan / box to 24.2 yuan / box.
April, the company undertook by the Ministry of Science and Technology of the National Science and Technology Small and Medium-sized Enterprises Technological Innovation Fund project "the development of the national five categories of new Chinese medicines XinKeShu drop pills" through the acceptance of the Shandong Provincial Department of Science and Technology.
September, the company's leading product Xinkexu Tablets "a kind of preparation of Xinkexu Tablets" was issued by the State Patent Bureau of the patent certificate, the patent period of 20 years.
November, the company was again recognized as a national high-tech enterprises.
December, the company's new drug Cerebral Blood Sparing Oral Liquid passed the approval, and obtained the production approval and new drug certificate issued by SFDA, with the approval number of State Drug License Z20070059.
December, the company's vice chairman Zhao Jun was elected as a deputy to the fifteenth session of the National People's Congress of Weifang City, and is a candidate for the Standing Committee of the National People's Congress of Weifang City.